Amgen’s MariTide Weight Loss Potential: Stock Outlook
MarketBeatAmgen’s shares fell 2.4% after-hours trading due to a mixed earnings release. MariTide, the company’s weight loss drug, is in Phase II FDA trials.
Amgen’s shares fell 2.4% after-hours trading due to a mixed earnings release. MariTide, the company’s weight loss drug, is in Phase II FDA trials.